MorphoSys AG (MOR) 2019年年度报告「NASDAQ」.pdf

1、annual report2019Annual Report 2019Clinical Pipeline Partnered Discovery ProgramsProduct Candidates in Clinical Development and One Product LaunchedMOST ADVANCED DEVELOPMENT STAGEPROGRAM/PARTNER INDICATIONTremfya(Guselkumab)/Janssen/J&J Psoriasis Gantenerumab/Roche Alzheimers disease Anetumab ravtan

2、sine(BAY94-9343)/Bayer Solid tumors BHQ880/Novartis Multiple myeloma Bimagrumab(BYM338)/Novartis Metabolic disease CNTO6785/J&J/Shandong Fontacea*Inflammation Ianalumab(VAY736)/Novartis Inflammation MAA868/Anthos Therapeutics Atrial fibrillation NOV-8(CMK389)/Novartis Pulmonary sarcoidosis NOV-9(LKA

3、651)/Novartis Diabetic eye diseases Setrusumab(BPS804)/Mereo/Novartis Brittle bone syndrome Tesidolumab(LFG316)/Novartis Eye diseases MOST ADVANCED DEVELOPMENT STAGEPROGRAM/PARTNER INDICATIONUtomilumab(PF-05082566)/Pfizer Cancer Xentuzumab(BI-836845)/BI Solid tumors BAY2287411/Bayer Cancer Elgemtuma

4、b(LJM716)/Novartis Cancer NOV-7(CLG561)/Novartis Eye diseases NOV-10(PCA062)/Novartis Cancer NOV-11/Novartis Blood disorders NOV-13(HKT288)/Novartis Cancer NOV-14(CSJ117)/Novartis Asthma CNTO3157/J&J*Inflammation Vantictumab(OMP-18R5)/Mereo Cancer PHASE 1PHASE 2PHASE 3LAUNCHEDPHASE 1PHASE 2PHASE 3LA

5、UNCHEDPipeline products are under clinical investigation and there is no guarantee any investigational product will be approved by regulatory authorities*Sublicensed for China,Hong Kong,Macao,Taiwan and South Korea.*Formerly PRV-300;Provention Bio terminated the sublicense and returned the program t

6、o Janssen in November 2019.Portfolio of Proprietary Development Programs MorphoSys,March 2020PHASE 1PHASE 2PHASE 3MOST ADVANCED DEVELOPMENT STAGEPROGRAM INDICATIONTafasitamab(MOR208)*B cell malignancies MOR202*Multiple myeloma Autoimmune Otilimab(MOR103/GSK3196165)*Rheumatoid arthritis MOR107(LP2-3)